Cellular Biomedicine Group Inc. (CBMG)’s Financial Results Comparing With Jaguar Health Inc. (NASDAQ:JAGX)

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) and Jaguar Health Inc. (NASDAQ:JAGX), both competing one another are Biotechnology companies. We will contrast their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellular Biomedicine Group Inc. N/A 1266.61 39.79M -2.21 0.00
Jaguar Health Inc. 5.20M 49.24 33.76M -2.60 0.00

Demonstrates Cellular Biomedicine Group Inc. and Jaguar Health Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 provides Cellular Biomedicine Group Inc. and Jaguar Health Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Cellular Biomedicine Group Inc. 0.00% -45.6% -38.7%
Jaguar Health Inc. -649.23% -253.4% -70%

Risk and Volatility

Cellular Biomedicine Group Inc. has a beta of 3.12 and its 212.00% more volatile than S&P 500. In other hand, Jaguar Health Inc. has beta of 1.18 which is 18.00% more volatile than S&P 500.

Liquidity

Cellular Biomedicine Group Inc.’s Current Ratio and Quick Ratio are 4.4 and 4.4 respectively. The Current Ratio and Quick Ratio of its competitor Jaguar Health Inc. are 0.3 and 0.2 respectively. Cellular Biomedicine Group Inc. therefore has a better chance of paying off short and long-term obligations compared to Jaguar Health Inc.

Analyst Recommendations

Cellular Biomedicine Group Inc. and Jaguar Health Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cellular Biomedicine Group Inc. 0 0 1 3.00
Jaguar Health Inc. 0 0 0 0.00

Cellular Biomedicine Group Inc.’s upside potential currently stands at 77.23% and an $26 average target price.

Institutional & Insider Ownership

The shares of both Cellular Biomedicine Group Inc. and Jaguar Health Inc. are owned by institutional investors at 22.1% and 12.6% respectively. 0.8% are Cellular Biomedicine Group Inc.’s share held by insiders. Competitively, Jaguar Health Inc. has 13.23% of it’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cellular Biomedicine Group Inc. -0.54% -5.49% -10.3% -1.02% -10.84% -6.34%
Jaguar Health Inc. -14.17% -22.47% -28.13% -62.9% -92.77% -24.61%

For the past year Cellular Biomedicine Group Inc.’s stock price has smaller decline than Jaguar Health Inc.

Summary

Cellular Biomedicine Group Inc. beats on 8 of the 10 factors Jaguar Health Inc.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy. The company has a strategic research collaboration with GE Healthcare Life Sciences China to co-develop industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing. Cellular Biomedicine Group Inc. was incorporated in 2001 and is headquartered in Cupertino, California.

Napo Pharmaceuticals, Inc., a human health company, focuses on developing and commercializing novel gastrointestinal prescription products from plants. Its products include Mytesi, an FDA approved product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Napo Pharmaceuticals, Inc. was formerly known as PS Pharmaceuticals, Inc. The company was founded in 2001 and is based in San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.